Katerzia™ (amlodipine) – New formulation approval
July 8, 2019 - The FDA approved Silvergate Pharmaceuticals’ Katerzia (amlodipine) oral suspension for treatment of hypertension in adults and children 6 years and older, to lower blood pressure; symptomatic treatment of chronic stable angina; treatment of confirmed or suspected vasospastic angina; to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure in patients with recently documented coronary artery disease (CAD) by angiography and without heart failure or an ejection fraction < 40%.
Top